The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedyaeva V.K.

Center for Expertise and Quality Control of Medical Care;
Financial Research Institute

Ryzhov A.O.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education

Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis

Authors:

Fedyaeva V.K., Ryzhov A.O.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2022;44(4): 42‑50

DOI: 10.17116/medtech20224404142

Views: 7961

Downloaded: 217

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Fedyaeva VK, Ryzhov AO. Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis. Medical Technologies. Assessment and Choice. 2022;44(4):42‑50. (In Russ.)
https://doi.org/10.17116/medtech20224404142

МСФ на ЯМ
Close metadata
Recommended articles:
Obesity grade I: a study of real clinical practice in the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):83-90
Sodium-glucose cotransporter 2 inhi­bitors in chro­nic heart failure: impact on life expe­ctancy in the Russian popu­lation. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):20-29
Oxidative stress prevention as an effe­ctive preventive stra­tegy in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(3):117-123
Dyna­mics of outpatient glycemic profile data in patients with type 2 diabetes receiving dietary fiber. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):55-65
The role of glutamine in the treatment of severe acute pancreatitis. Russian Journal of Anesthesiology and Reanimatology. 2024;(4):97-101
Macrovascular and microvascular complications of type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(8):94-100
Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chro­nic kidney disease. Russian Journal of Preventive Medi­cine. 2024;(8):114-120
Continuum of type 2 diabetes mellitus and its como­rbidity with other soma­tic diseases. Russian Journal of Preventive Medi­cine. 2024;(9):123-129
In-hospital diuretic resi­stance as a risk factor for poor long-term prognosis in chro­nic heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):532-539
Modu­lation of oxidative stress as an early symptom of sarcopenia in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(10):108-116

OBJECTIVE

A network meta-analysis (indirect comparison and mixed comparison) of the effects of empagliflozin and dapagliflozin on the incidence of adverse cardiovascular outcomes in patients with type 2 diabetes mellitus (DM2) and previous cardiovascular diseases.

MATERIAL AND METHODS

A systematic review and selection of studies were performed in the PubMed and EMBASE databases. A network meta-analysis was performed in accordance with the guidelines for indirect comparisons and criteria for assessing the methodological quality of indirect comparisons. Indirect comparisons were made using the methodology presented by H.C. Bucher et al. (1997).

RESULTS

We enrolled 3 randomized controlled trials (RCTs) for inclusion in indirect comparison network (one RCT for empagliflozin and two RCTs for dapagliflozin). Moreover, additional searching revealed one head-to-head comparative real-life study of dapagliflozin and empagliflozin that was included in a mixed comparison network. We found no difference in clinical efficacy of dapagliflozin and empagliflozin for preventing adverse cardiovascular events in patients with DM2 and previous cardiovascular diseases.

Keywords:

type 2 diabetes mellitus
dapagliflozin
empagliflozin
network meta-analysis

Authors:

Fedyaeva V.K.

Center for Expertise and Quality Control of Medical Care;
Financial Research Institute

Ryzhov A.O.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education

Received:

14.09.2022

Accepted:

11.10.2022

List of references:

  1. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus In Russian Federation: clinical and statistical report according to the federal diabetes registry. Saharnyj diabet. 2017;20(1):13-41. (In Russ.). https://doi.org/10.14341/DM8664
  2. Klinicheskie rekomendacii Saharnyj diabet 2 tipa u vzroslyh. Rossijskaya associaciya endokrinologov. 2022. (In Russ.). https://cr.minzdrav.gov.ru/recomend/290_2
  3. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.  https://doi.org/10.1016/S0140-6736(18)32590-X
  4. Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovascular Diabetology. 2020;19(1):1-10.  https://doi.org/10.1186/s12933-020-01067-8
  5. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet. Diabetes and Endocrinology. 2016;4(5):411-419.  https://doi.org/10.1016/S2213-8587(16)00052-8
  6. Li C, Liang Sh, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PloS ONE. 2021;16(2):e0244689. https://doi.org/10.1371/journal.pone.0244689
  7. Rebrova OYu, Fedyaeva VK., Khachatryan GR. Adaptation and Validation of the Cochrane Questionnarie to Assess Risks of Bias in Randomized Controlled Trials. Medicinskie tekhnologii. Ocenka i vybor. 2015;19(1):9-17. (In Russ.).
  8. Omelyanovskiy VV, Avxentyeva MV, Sura MV, Khachatryan GR, Fedyaeva VK. Metodicheskie rekomendacii po provedeniyu nepryamyh sravnenij lekarstvennyh preparatov. M. 2017. (In Russ.).
  9. Rebrova OYu, Fedyaeva VK. Questionnaire for assessing the reliability of network meta-analysis (including indirect and mixed comparisons). Medicinskie tekhnologii. Ocenka i vybor. 2016;24(2):9-15. (In Russ.).
  10. Bucher HC, Gordon H, Lauren EG, Walter SD. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Epidemiology. 1997;50(6):683-691.  https://doi.org/10.1016/s0895-4356(97)00049-8
  11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. https://doi.org/10.1056/NEJMoa1504720
  12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2019;380(4):347-357.  https://doi.org/10.1056/NEJMoa1812389
  13. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. Jama. 2020;323(14):1353-1368. https://doi.org/10.1001/jama.2020.1906
  14. Shao SC, Chang K-Ch, Hung M-J, Yang N-I, Chan Y-Y, Chen H-Yu, et al. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi- institutional cohort study. Cardiovascular Diabetology. 2019;18(1):1-15.  https://doi.org/10.1186/s12933-019-0919-9
  15. Rebrova OYu. Statisticheskij analiz medicinskih dannyh. Primenenie paketa prikladnyh programm Statistica. M.: Media Sfera; 2006. (In Russ.).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.